Monitoring of anticoagulant effects of dabigatran in everyday practice: first experience in 32 Polish patients

Czubek, Urszula; Góralczyk, Tadeusz; Zalewski, J; Undas, Anetta

doi:10.20452/pamw.2415

Cited by 10 publications

(10 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The blood levels connected with DOACs vary from a few ng/mL prior to drug administration ("trough"), to several hundred ng/mL, if the sample is taken 2-4 h after the drug's intake ("peak") ( Table 2). The first Polish experience with determining dabigatran and rivaroxaban in the circulating blood was published in 2014 [49][50][51]. Table 3 shows the effects of DOACs on coagulation assays.…”

Section: Effect Of Doacs On Routine Coagulation Testsmentioning

confidence: 99%

Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment

Undas

Góralczyk

2016

Adv Clin Exp Med

Self Cite

View full text Add to dashboard Cite

Section: Effect Of Doacs On Routine Coagulation Testsmentioning

confidence: 99%

Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment

Undas

Góralczyk

2016

Adv Clin Exp Med

Self Cite

View full text Add to dashboard Cite

“…The most common tests used for this purpose are calibrated quantitative anti-factor-Xa assays for factor Xa inhibitors or the Hemoclot assays measuring dilute TT in patients on dabigatran. These tests may not be readily available, but in some labs they are performed 24/7 and their results are available up to 2 h [51, 52, 55]. …”

Section: Bleeding Managementmentioning

confidence: 99%

Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation

Zalewski¹,

Undas²

2016

pwki

Self Cite

View full text Add to dashboard Cite

The dynamic evolution of therapeutic options including the use of vitamin K antagonists (VKA), non-vitamin K oral anticoagulants (NOAC), more potent antiplatelet drugs as well as new generation drug-eluting stents could lead to the view that the current recommendations on the management of patients with percutaneous coronary intervention (PCI) requiring oral anticoagulation do not keep up with the results of several clinical studies published within the last 5 years. In the present overview, we summarize the recent advances in antithrombotic management used in atrial fibrillation patients undergoing PCI for stable coronary artery disease or acute coronary syndrome (ACS). The safety and efficacy of prasugrel and ticagrelor taken with oral anticoagulants also remain to be established in randomized trials; therefore the P2Y12 inhibitor clopidogrel on top of aspirin or without is now recommended to be used together with a VKA or NOAC. It is still unclear which dose of a NOAC in combination with antiplatelet agents and different stents should be used in this clinical setting and whether indeed NOAC are safer compared with VKA in such cardiovascular patients. Moreover, we discuss the use of anticoagulation in addition to antiplatelet therapy for secondary prevention in patients with ACS. To minimize bleeding risk in anticoagulated patients following PCI or ACS, the right agent should be prescribed to the right patient at the right dose and supported by regular clinical evaluation and laboratory testing, especially assessment of renal function when a NOAC is used.

show abstract

“…The effect of apixaban can be qualitatively evaluated with modified PT, while dabigatran -with dilute thrombin time or anti-factor II assay. When necessary and feasible, concentration of NOACs can be directly measured in plasma [79,80].…”

Section: Oral Anticoagulants In Copdmentioning

confidence: 99%

Arterial and Venous Thromboembolism in Chronic Obstructive Pulmonary Disease: From Pathogenic Mechanisms to Prevention and Treatment

Mejza

Lamprecht

Niżankowska‐Mogilnicka

et al. 2015

Advances in Respiratory Medicine

Self Cite

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) affects approximately 10% of adults older than 40 years and is an important causes of disability and death in elderly subjects. A large proportion of COPD patients suffer from cardiovascular comorbidities. Thromboembolic events contribute considerably to morbidity and mortality in these subjects. This review summarizes the current evidence regarding the association of COPD with increased thromboembolic risk. We discuss multiple mechanisms potentially linking these conditions and available pharmacological interventions reducing the risk of thrombotic arterial and venous events with special attention paid to new oral anticoagulants.

show abstract

Monitoring of anticoagulant effects of dabigatran in everyday practice: first experience in 32 Polish patients

Cited by 10 publications

References 3 publications

Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment

Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment

Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation

Arterial and Venous Thromboembolism in Chronic Obstructive Pulmonary Disease: From Pathogenic Mechanisms to Prevention and Treatment

Contact Info

Product

Resources

About